KDR and neoplasm: VEGF receptor 2 (VEGFR2) inhibition was reported to enhance the anti-tumor effects of EGFR-TKI in EGFR-mutated NSCLC models by inhibiting not only tumor angiogenesis but also oncogenic signaling in cancer cells, implying a potent role of VEGFR2 signaling in EGFR-mutated NSCLC cell proliferation [20].